Michael Parini Biography and Net Worth

Michael J. Parini serves as Chief Executive Officer of Freeline and is also a member of the Company’s Board of Directors. Mr. Parini joined Freeline in March of 2021 as the Company’s President and Chief Operating Officer. Mr. Parini brings more than 20 years’ experience in the biopharmaceutical industry most recently serving as Executive Vice President and Chief Administrative, Legal and Business Development Officer at Vertex Pharmaceuticals, Inc. from March 2020 until February 2021 and as Executive Vice President and Chief Legal and Administrative Officer from January 2016 to March 2020. Prior to joining Vertex, he spent more than a decade at Pfizer Inc., where he served in multiple leadership roles within the company's global legal team, including Senior Vice President and Associate General Counsel. Prior to joining Pfizer, Mr. Parini served as a healthcare attorney at Akin, Gump, Strauss, Hauer & Feld, L.L.P. in Washington, D.C., where he provided legal counsel on federal and state regulatory and policy issues. Mr. Parini is a member of the New York and District of Columbia bars. He received a Bachelor of Arts degree in American Government from Georgetown University and a Juris Doctor degree from Georgetown University Law Center.

What is Michael Parini's net worth?: The estimated net worth of Michael Parini is at least $28.16 million as of February 5th, 2021. Mr. Parini owns 59,157 shares of Vertex Pharmaceuticals stock worth more than $28,157,549 as of October 31st. This net worth evaluation does not reflect any other investments that Mr. Parini may own. Learn More about Michael Parini's net worth.
How do I contact Michael Parini?: The corporate mailing address for Mr. Parini and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Michael Parini's contact information.
Has Michael Parini been buying or selling shares of Vertex Pharmaceuticals?: Michael Parini has not been actively trading shares of Vertex Pharmaceuticals during the past quarter. Most recently, Michael Parini sold 1,930 shares of the business's stock in a transaction on Friday, February 5th. The shares were sold at an average price of $215.00, for a transaction totalling $414,950.00. Following the completion of the sale, the executive vice president now directly owns 59,157 shares of the company's stock, valued at $12,718,755. Learn More on Michael Parini's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 24 times. They sold a total of 96,063 shares worth more than $43,158,852.08. The most recent insider tranaction occured on August, 30th when Chairman Jeffrey M Leiden sold 3,784 shares worth more than $1,888,216.00. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 8/30/2024.

Michael Parini Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/5/2021	Sell	1,930	$215.00	$414,950.00	59,157
2/3/2021	Sell	400	$216.56	$86,624.00	35,276
7/13/2020	Sell	2,125	$292.05	$620,606.25	28,963
4/29/2020	Sell	2,125	$254.95	$541,768.75	28,963
1/22/2020	Sell	1	$237.50	$237.50	35,004
1/13/2020	Sell	2,125	$226.78	$481,907.50	37,128
1/6/2020	Sell	4,250	$222.00	$943,500.00	39,253
11/13/2019	Sell	4,892	$205.50	$1,005,306.00	39,895
10/17/2019	Sell	4,250	$177.80	$755,650.00	39,253
10/14/2019	Sell	2,125	$174.06	$369,877.50	37,128
8/5/2019	Sell	2,330	$175.28	$408,402.40	34,395
7/12/2019	Sell	2,125	$175.27	$372,448.75	37,128
7/5/2019	Sell	4,250	$179.11	$761,217.50	39,253
5/3/2019	Sell	1,622	$172.06	$279,081.32	37,332
2/11/2019	Sell	12,136	$180.22	$2,187,149.92	60,050
2/4/2019	Sell	2,330	$189.19	$440,812.70	38,489
2/1/2019	Sell	3,450	$190.92	$658,674.00
1/14/2019	Sell	2,125	$186.71	$396,758.75	41,734
1/4/2019	Sell	4,250	$165.90	$705,075.00	43,859
10/12/2018	Sell	2,125	$177.20	$376,550.00	41,734
10/4/2018	Sell	4,250	$191.58	$814,215.00	43,859
7/12/2018	Sell	2,125	$175.02	$371,917.50	41,734
7/5/2018	Sell	4,250	$168.38	$715,615.00	43,859
5/3/2018	Sell	2,330	$149.50	$348,335.00	41,939
4/26/2018	Sell	40,764	$159.29	$6,493,297.56	42,123
2/12/2018	Sell	12,136	$153.41	$1,861,783.76	74,652
11/3/2017	Sell	2,330	$149.50	$348,335.00	31,139
10/12/2017	Sell	2,125	$152.93	$324,976.25
8/3/2017	Sell	2,330	$155.72	$362,827.60	31,139
7/19/2017	Sell	10,829	$161.00	$1,743,469.00	37,309

Michael Parini Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $475.98

$468.98

$477.70

50 Day Range

MA: $474.81

$448.60

$498.73

2 Week Range

Now: $475.98

$341.90

$510.64

Volume

1,375,027 shs

Average Volume

1,166,011 shs

Market Capitalization

$122.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.